Pfizer & BioNTech to supply Singapore with vaccine candidate to combat COVID-19

SINGAPORE and MAINZ, GERMANY, 14 December 2020 — Pfizer Singapore and BioNTech SE today announced an agreement with the Ministry of Health in Singapore to supply their COVID-19 mRNA vaccine candidate (BNT162b2) through 2021, following emergency use authorization from U.S. Food and Drug Administration (FDA) and interim authorization for pandemic supply from Singapore Health Sciences Authority (HSA).

Financial details of the agreement were not disclosed, but the terms were based on the timing of delivery and the volume of doses. As requested by the Government of Singapore, deliveries are planned through 2021.

“We are deeply honored to work with the Singapore government and to marshal our scientific and manufacturing resources toward our shared goal of bringing our COVID-19 vaccine to the people in Singapore as quickly as possible,” said Erika Pagani, Pfizer Singapore Country Manager. “In the face of this global health crisis, Pfizer’s purpose – breakthroughs that change patients’ lives – has taken on an even greater urgency. Our hope is that, following regulatory success, our vaccine will help make this happen.”

“I would like to thank the Singapore government for its support and putting trust in our ability to develop a vaccine that, we believe, has the potential to help address this global pandemic threat. Our goal remains to deliver a global supply of a safe and effective COVID-19 vaccine for many people around the world, as quickly as we can,” said Sean Marett, Chief Business and Chief Commercial Officer at BioNTech.  

In addition to engagements with governments, Pfizer and BioNTech have provided an expression of interest for possible supply to the COVAX Facility, a mechanism established by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and World Health Organization (WHO) that aims to provide governments, including those in the emerging markets, with early access to a large portfolio of COVID-19 candidate vaccines using a range of technology platforms, produced by multiple manufacturers across the world.

Based on current projections, Pfizer’s and BioNTech’s combined manufacturing network has the potential to supply globally up to 1.3 billion doses by the end of 2021 (subject to manufacturing capacity and regulatory approval or authorization).